Search

In the present study we have used cell culture assays in order to assess the damage in the haematopoietic system 1 year after peripheral blood stem cell transplantation (PBSCT), and to establish at what level, haematopoietic progenitor cells (HPC) or stroma, this damage occurs. Thirty-one patients, nine breast cancer (BC), 17 non-Hodgkin lymphoma (NHL) and five Hodgkin disease (HD), who had received autologous PBSCT were included. Forty-eight normal subjects who had given informed consent were used as controls. Results were also compared with a matched group of patients (25 cases) prior to PBSCT. Progenitor cells were analysed using CFU-GM and plastic adherent delta (PΔ) assays. Long-term bone marrow cultures (LTBMC) in one and two stages were established. One year after transplant both the number of committed progenitor cells and the CFU-GM production in LTBMC were significantly reduced in the three groups of patients when compared with controls (P < 0.05 or P < 0.01). two-stage ltbmc experiments showed that the impairment in cfu-gm production was due to damage in both patients’ stroma and haematopoietic progenitor cells (hpc). all patients, except those with hd, showed a decreased stromal layer confluence (P < 0.05), with significant differences in cell composition as compared to normal bone marrow (P = 0.001). When all these variables were compared with pretransplant results, we observed that stroma formation was significantly lower after PBSCT (P < 0.05), while the number of progenitor cells analysed by the pδ assay was significantly increased (P < 0.05). we can conclude that even 1 year after pbsct, both the committed hpc and bm stroma remain damaged. [ABSTRACT FROM AUTHOR]

In the present paper, we evaluate tolerability, outcome and prognostic factors in patients with poor prognosis non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease (HD) when uniformly treated with BCNU, etoposide, cytarabine and melphalan (BEAM) and autologous stem cell transplant (ASCT). One hundred and forty-eight patients with NHL (n = 112) or HD (n = 36) received BEAM followed by infusion of bone marrow (n = 55), peripheral blood stem cells (n = 79) or both (n = 14). Twenty-eight patients had low-grade lymphoma (LGL), 68 intermediate- and 16 high-grade lymphoma (IGL). Within the NHL group, 21 patients were in 2nd or subsequent complete remission (CR) at transplant, 34 had sensitive disease and 11 resistant disease; 46 patients were transplanted in 1st CR due to the presence of 2 adverse prognostic features at diagnosis or to a slow CR. Of the HD patients at transplant 17 had active disease, 16 were in 2 CR and three in 1st CR. The overall percentage of toxic deaths was 5.4%, while in the group of patients transplanted with PBSC it was only 1.3%. NHL patients: 78% were in CR following ASCT, including 25 out of 45 patients (56%) who were transplanted with active disease. Only two of the 11 patients transplanted with resistant disease achieved CR. Incidence of overall survival (OS) and disease-free survival (DFS) at 3 years was 65 and 75%, respectively. As far as histology was concerned, OS was significantly better for patients with LGL in comparison with IGL (88 vs 56%) (P = 0.002). DFS was significantly higher for patients transplanted in first CR or first partial remission (PR) than it was for those transplanted in a later CR or PR (86 vs 53%) (P = 0.02). Multivariate analysis for OS showed that histology, bulky disease, poor performance status at transplant and achievement of CR were independent prognostic factors. In addition, a high number of infused MNC was associated with poor DFS. HD patients: 30 (83%) were in CR after... [ABSTRACT FROM AUTHOR]

Cites a study which illustrates a case displaying morphological and immunological criteria of acute nonlymphoblastic leukemia (ANLL) that showed a rearrangement of the immunoglobulin lambda locus. Details of patients analyzed in the study; Southern blot analysis of the genes of the patient; Issues related to rearrangement of the genes.

Reports on the study conducted on a patient with a B cell non-Hodgkin's lymphoma who developed a myelodysplastic syndrome (MDS) 27 months after autologous peripheral blood stem cell transplantation. Results of the cytogenetic analysis performed on bone marrow cells at the time of MDS diagnosis; Presence of clonal karyotypic abnormalities in the leukepheresis product; Emphasis on the need to apply modified diagnostic criteria.

Comments on an article about rhabdomyolysis associated with septicemia after a bone marrow transplantation procedure. Information on rhabdomyolysis; Diagnosis of the disease; Microorganism associated with the disease.